Please login to the form below

Not currently logged in
Email:
Password:

ADHD

This page shows the latest ADHD news and features for those working in and with pharma, biotech and healthcare.

BenevolentAI raises $115m to fund drug development

BenevolentAI raises $115m to fund drug development

The drug has been licensed from Johnson &Johnson (J&J), which was originally developing it for attention-deficit hyperactivity disorder (ADHD).

Latest news

More from news
Approximately 18 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    contingent payments for the ADHD company Neurovance; Shanghai Fosun paid $90m for a majority interest in Breas (see above); Ascendis Health paid R375m ($29m) for the Southern Africa operations of Cipla ... 320. Neurovance. Otsuka. Acquisition. Portfolio,

  • A rare talent A rare talent

    It allowed us to solidify our position as the world's largest rare disease company and we now are the leaders in haematology, lysosomal storage disorders with strong capabilities in ADHD

  • Challenging perceptions Challenging perceptions

    We try to be recognised as patient-centric by supporting and helping the overall ADHD community. ... Harnessing technology. Shire's communications efforts in ADHD have for some time included digital technology.

  • Pharma deals in February 2015 Pharma deals in February 2015

    in-house clinical and preclinical pipeline targeting serious diseases with blockbuster potential eg Alzheimer's disease, ADHD, metabolic disease, schizophrenia, migraine. ... Its initial development was focused on ADHD and other neurological diseases.

  • Experience me: building engagement through experience Experience me: building engagement through experience

    Janssen's award-winning campaigns in ADHD are a great example of this approach in operation.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Shire elects new chair Shire elects new chair

    During that time Shire has grown substantially, although has struggled in recent years with generic competition for big-selling attention deficit-hyperactivity disorder (ADHD) drug Adderall XR and plans to downsize

  • Bray Leino opens health and wellbeing PR practice Bray Leino opens health and wellbeing PR practice

    She has worked on campaigns for ADHD brands and public affairs for Shire Pharmaceuticals: cardiology products for AstraZeneca, Sanofi and Eli Lilly; mental health for Wyeth; diagnostics and devices for Roche

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Havas Lynx Scoops Healthcare Agency of the Year at Cannes Lions 2018

    The second silver was in the Art Direction category for its inspired and inventive Attention Deficit Hyperactivity Disorder (ADHD) Rollercoaster campaign.

  • ADHD perspectives series

    The ADHD in practice editorial board looks to represent this multi-disciplinary team providing insight and opinion. ... ADHD community can work together to provide the personalised 'scaffolding' from their perspective.

  • Powering behaviour change with human insights

    Lets consider for instance ADHD diagnosis in the UK, research has found that diagnosis of ADHD in school-age children grew from less than one percent in the 1990s to about

  • ADHD perspectives series

    The ADHD in practice editorial board looks to represent this multi-disciplinary team providing insight and opinion. ... ADHD community can work together to provide the personalised 'scaffolding' from their perspective.

  • Just::Health Communications

    Having a lively mix of businesses and charities of all sizes, with challenges in everything from asthma to ADHD, epilepsy to oncology, arthritis to sexual health, keeps thinking fresh.

More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics